Amicus Therapeutics Inc’s recently made public that its President and CEO Campbell Bradley L unloaded Company’s shares for reported $87496.0 on Apr 01 ’24. In the deal valued at $11.67 per share,7,500 shares were sold. As a result of this transaction, Campbell Bradley L now holds 886,654 shares worth roughly $10.29 million.
Then, MCGLYNN MARGARET G sold 7,500 shares, generating $100,500 in total proceeds. Upon selling the shares at $13.40, the Director now owns 59,289 shares.
Before that, MCGLYNN MARGARET G sold 7,500 shares. Amicus Therapeutics Inc shares valued at $99,675 were divested by the Director at a price of $13.29 per share. As a result of the transaction, MCGLYNN MARGARET G now holds 59,289 shares, worth roughly $0.69 million.
Morgan Stanley upgraded its Amicus Therapeutics Inc [FOLD] rating to an Overweight from a an Equal-weight in a research note published on December 19, 2023; the price target was increased to $20 from $15. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in early September with a ‘”an Equal-weight”‘ rating. SVB Leerink revised its rating on January 14, 2022. It rated FOLD as “an Outperform” which previously was an “a Mkt perform”.
Price Performance Review of FOLD
On Monday, Amicus Therapeutics Inc [NASDAQ:FOLD] saw its stock fall -1.02% to $11.60. Over the last five days, the stock has lost -1.28%. Amicus Therapeutics Inc shares have fallen nearly -18.25% since the year began. Nevertheless, the stocks have risen 4.88% over the past one year. While a 52-week high of $14.57 was reached on 01/02/24, a 52-week low of $9.70 was recorded on 04/03/24. SMA at 50 days reached $12.53, while 200 days put it at $12.32. A total of 1.54 million shares were traded, compared to the trading of 4.27 million shares in the previous session.
Levels Of Support And Resistance For FOLD Stock
The 24-hour chart illustrates a support level at 11.46, which if violated will result in even more drops to 11.31. On the upside, there is a resistance level at 11.78. A further resistance level may holdings at 11.96. The Relative Strength Index (RSI) on the 14-day chart is 42.90, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.05, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 56.64%. Stochastics %K at 42.77% indicates the stock is a holding.
How much short interest is there in Amicus Therapeutics Inc?
A steep rise in short interest was recorded in Amicus Therapeutics Inc stocks on Mar 15, 2024, growing by 5.62 million shares to a total of 32.4 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 26.78 million shares. There was a rise of 17.35%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 11.02% of the overall stock float, the days-to-cover ratio (short ratio) rose to 8.3.
